Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - NSCLC, metastatic 2

2886 - Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: data from KEYNOTE-407


21 Oct 2018


Poster Discussion session - NSCLC, metastatic 2


Cytotoxic Therapy;  Immunotherapy

Tumour Site


Julien Mazieres


J. Mazieres1, D. Kowalski2, A. Luft3, D. Vicente4, A. Tafreshi5, M. Gümüş6, K. Laktionov7, B. Hermes8, I. Cicin9, J. Rodríguez-Cid10, J. Wilson11, T. Kato12, R. Ramlau13, S. Novello14, S. Reddy15, B. Piperdi16, X. Li16, T. Burke16, L. Paz-Ares17

Author affiliations

  • 1 Centre Hospitalier, Universitaire de Toulouse, 31400 - Toulouse/FR
  • 2 Oncology, Maria Skłodowska-Curie Institute of Oncology, 00-001 - Warsaw/PL
  • 3 Oncology, Leningrad Regional Clinical Hospital, 194291 - St. Petersburg/RU
  • 4 Clinical Oncology Department, Hospital Universitario Virgen Macarena, 41009 - Seville/ES
  • 5 Wollongong Oncology, University of Wollongong, 2522 - Wollongong/AU
  • 6 Faculty Of Medicine, Istanbul Medeniyet University Hospital, 34732 - Istanbul/TR
  • 7 Clinical Oncology Research Institute, N.N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU
  • 8 Oncology, Universitätskinikum Tübingen, 72076 - Tübingen/DE
  • 9 Department Of Medical Oncology, Trakya University, 22030 - Edirne/TR
  • 10 Oncology Center, Medica Sur Hospital, 14050 - Mexico City/MX
  • 11 Department Of Medicine, Humber River Regional Hospital, M6A 3B5 - Toronto/CA
  • 12 Division Of Thoracic Oncology, Kanagawa Cancer Center, 2418515 - Yokohama/JP
  • 13 Department Of Oncology, Poznan University of Medical Sciences, 61-701 - Poznan/PL
  • 14 Department Of Oncology, University of Turin, 10124 - Orbassano/IT
  • 15 Cancer Institute, Northside Hospital, 30342 - Atlanta/US
  • 16 Oncology, Merck & Co., Inc., 07033 - Kenilworth/US
  • 17 Hospital Universitario 12 De Octubre, CNIO, Universidad Complutense and Ciberonc, 28041 - Madrid/ES


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2886


In the randomized, double-blind, phase 3 KEYNOTE-407 study, pembrolizumab (pembro) plus carboplatin and paclitaxel or nab-paclitaxel improved OS, PFS, and ORR and had a manageable safety profile compared with placebo (pbo) plus carboplatin and paclitaxel or nab-paclitaxel as first-line therapy for patients with metastatic squamous NSCLC. Patient-reported outcomes (PROs) were a prespecified exploratory endpoint of KEYNOTE-407 (NCT02775435).


559 patients with previously untreated stage IV squamous NSCLC, ECOG PS 0–1, and measurable disease per RECIST v1.1 were randomized 1:1 to receive 4 cycles of pembro 200 mg Q3W or pbo Q3W plus carboplatin AUC 6 and paclitaxel 200 mg/m2 Q3W or nab-paclitaxel 100 mg/m2 QW, followed by pembro or pbo monotherapy for up to 35 cycles total. The EORTC QLQ-C30 and QLQ-LC13 were administered at cycles 1–7, then every 3 cycles up to week 48. Prespecified key PROs were change from baseline to weeks 9 and 18 in the QLQ-C30 global health status (GHS)/quality of life (QoL) score and time to 10-point deterioration in the composite endpoint of cough, chest pain, or dyspnea. P values are 2-sided and nominal.


PRO analyses included 554 and 553 patients who completed ≥1 QLQ-C30 or ≥1 QLQ-LC13 assessment, respectively, and received ≥1 administration of study treatment. Compliance rates were similar between the groups and instruments (baseline, ~93%–94%; week 9, ~84%; week 18, ~87%). Mean QLQ-C30 GHS/QoL baseline scores were 63.9 in the pembro combination group and 62.7 in the pbo combination group. At weeks 9 and 18, the mean score for QLQ-C30 GHS/QoL improved from baseline in the pembro combination group and decreased in the pbo combination group (least squares mean difference between groups: week 9, 3.6 points [95% CI, 0.3–6.9], P=0.0337; week 18, 4.9 points [95% CI, 1.4–8.3], P=0.0060). Median time to deterioration in the composite endpoint of cough, chest pain, or dyspnea was not reached in either group (HR, 0.79 [95% CI, 0.58–1.06]; P=0.125).


Addition of pembro to chemotherapy maintained or improved HRQoL measurements over chemotherapy alone, supporting its use as first-line therapy for metastatic squamous NSCLC.

Clinical trial identification

ClinicalTrials.gov number NCT02775435, originally posted May 17, 2016

Editorial Acknowledgement

Medical writing and editorial assistance was provided by C4 MedSolutions, LLC (Yardley, PA), a CHC Group company. This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.